Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA), Tangible Scientific, and Inductive Bio launched ADME-One™, a high-throughput Tier 1 ADME platform integrating automated data generation, AI-driven human PK projection, and compound management.
The U.S.-based service targets earlier, data-rich small molecule decision-making at pricing described as several times lower than typical industry options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Launch of ADME-One, integrating Tier 1 ADME assays, AI PK projection, and logistics
- Automated Boston lab delivers standardized, AI-ready Tier 1 ADME data
- Inductive Bio models validated by wins in 2025 ASAP and 2026 ExpansionRx OpenADMET challenges
- Workflow priced at levels described as several times below industry standard
- U.S.-based workflow positioned for reshoring and data sovereignty needs
- Addition of VP Small Molecules to lead ADME-One product strategy
Negative
- None.
News Market Reaction – DNA
On the day this news was published, DNA gained 3.33%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.7% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $18M to the company's valuation, bringing the market cap to $565.59M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Negative | -13.5% | Revenue fell sharply with continued losses; stock dropped double digits. |
| Apr 30 | Earnings date set | Neutral | +12.8% | Announced timing and format for upcoming Q1 2026 results call. |
| Mar 02 | Platform launch | Positive | +4.4% | Introduced Ginkgo Cloud Lab for remote access to autonomous lab. |
| Feb 26 | FY25 earnings/shift | Negative | -30.5% | Reported revenue declines, large losses, and biosecurity divestiture plan. |
| Feb 19 | Earnings date set | Neutral | +8.3% | Scheduled Q4 and FY25 results presentation with webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-specific launches and strategic updates have often coincided with share price gains, while earnings reports tied to revenue declines have seen sharp selloffs.
Over the last six months, DNA has pivoted toward autonomous labs and higher-value platform offerings. Earnings on Feb 26, 2026 and May 7, 2026 showed declining revenue and sizable losses, with negative price reactions. In contrast, platform launches like Ginkgo Cloud Lab on Mar 2, 2026 and scheduling announcements for earnings dates were met with positive moves. Today’s ADME-One launch fits the pattern of emphasizing AI-enabled, automation-driven services after divesting the biosecurity unit.
Key Terms
adme medical
pharmacokinetic medical
pk medical
admet medical
plasma protein binding medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification
ADME-One is designed to break a cycle that has constrained small molecule drug discovery for decades: Due to the economic limitations of traditional data generation methods, comprehensive ADME profiling is typically reserved for lead optimization after teams have determined their lead series. When liabilities surface at this later stage, the cost of fixing them is highest. ADME-One changes that calculus, allowing discovery teams to characterize entire series with integrated, data-driven decisions in stages as early as hit identification. The result is fewer surprises, fewer wasted synthesis cycles, and a better ability to identify and test the compounds most likely to succeed in humans.
A Single, Integrated Workflow Across Three Category Leaders
ADME-One unites three best-in-class capabilities in one packaged service:
- Ginkgo Datapoints: Data Generation. All five Tier 1 assays (microsomal stability, cell permeability, kinetic solubility, CYP inhibition, and plasma protein binding) are executed end-to-end in Ginkgo's automated laboratory in
Boston . Validated, standardized workflows produce AI-ready data without the variability of manual handling. - Inductive Bio: AI-Driven Contextualization. Inductive Bio's Compass platform turns the experimental panel into actionable human PK projections, integrating disparate individual ADME datapoints into a single multiparameter optimization endpoint that guides compound prioritization. The company's ADMET models are independently validated as best-in-class, having recently won both the 2025 ASAP and 2026 ExpansionRx OpenADMET blind prediction challenges, two of the most rigorous public benchmarks in the field.
- Tangible Scientific: Compound Management. Customers submit compounds and receive results. Tangible handles compound intake, plating, real-time tracking, and management for every ADME-One order, eliminating the logistics overhead that typically accompanies outsourced ADME work.
Impact on Drug Discovery
"With ADME-One, we're both lowering the price of an ADME panel and transforming when and to what extent this data is effectively used in the drug discovery process," said John Androsavich, General Manager at Ginkgo Datapoints. "For the first time, chemists can efficiently characterize the entire series in hit identification. That fundamentally changes the quality of decisions teams make at the earliest stages of a program, where derisking is most needed. By combining automation, AI, and integrated logistics in a single domestic workflow, Ginkgo and our partners are demonstrating and making available the workflows that the Bio × AI era of drug discovery demands."
"We are at a moment in the application of AI to medicine where discovery teams can generate and prioritize drug candidates faster than their physical operations can validate them. Manifests get reconciled by hand, orders move through email threads, and senior scientists spend hours per week chasing shipments and tracking inventory across vendors. Tangible's role in ADME-One is to make the handoffs between design and data disappear, so discovery teams can validate candidates at the speed their AI investments promised," said Adham Chebbani, Co-founder of Tangible Scientific.
"The question every drug program is really trying to answer is which compound is most likely to achieve a safe and efficacious human dose," said Josh Haimson, CEO at Inductive Bio. "The Inductive platform lets drug hunters rank millions of compounds by predicted human dose, using state-of-the-art AI models that placed first in both OpenADMET competitions. With ADME-One, we move those compounds from the virtual lab to the wet lab in a tight feedback loop, surfacing the most promising ideas from day one. This is what AI-driven discovery looks like in practice: better decisions earlier, fewer dead ends later, and higher-quality medicines reaching patients sooner."
Together, the three partners deliver unified, contextualized ADME data in a streamlined workstream with rapid turnaround, all at a price point several times lower than the industry standard. Against the backdrop of
To drive ADME-One's product strategy, Ginkgo Datapoints has added Jonathan Grob to its leadership team as Vice President of Small Molecules. Grob brings deep expertise in medicinal chemistry, automation, and technology development from prior roles at Novartis and Valo Health. His hire reflects Ginkgo's continued investment in building the strongest next-generation, AI-enabled small molecule drug discovery team in the industry, complementing the platform's automation and data generation capabilities with seasoned scientific leadership.
Get Started on ADME-One
Drug discovery teams interested in early access or volume engagements are encouraged to contact Ginkgo Datapoints, Tangible Scientific, or Inductive Bio directly. Existing customers can contact their account representative to enable access to ADME-One. New customers can email datapoints@ginkgobioworks.com and visit our website at https://datapoints.ginkgo.bio/services#small-molecule-adme
The three partners host the New England Drug Metabolism Discussion Group (NEDMDG) meeting on May 27 in
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
About Tangible Scientific
Tangible Scientific is a tech-enabled compound management platform that removes the logistics bottleneck between design and data. From its
About Inductive Bio
Inductive builds virtual chemistry labs that help drug hunters design higher quality molecules, faster. Inductive's virtual labs are designed to scale proven scientific best practices across medicinal chemistry, computational chemistry, DMPK, and safety, enabling teams to make higher-quality decisions consistently throughout discovery. Inside these virtual labs, AI chemistry assistants, predictive ADMET and PK models, and human-relevant digital organ technologies work together to help scientists evaluate more hypotheses in silico and surface key risks earlier. The most promising molecules move from the virtual lab to the wet lab in a tight feedback loop that accelerates the advancement of high-quality molecules. Inductive already powers dozens of active discovery programs, including collaborations with leading biopharma partners. For more information, please visit www.inductive.bio.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's autonomous labs. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the
INDUCTIVE BIO MEDIA CONTACT: media@inductive.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-datapoints-tangible-scientific-and-inductive-bio-launch-adme-one-a-high-throughput-adme-platform-that-brings-pharmacokinetic-projection-earlier-in-drug-discovery-302782095.html
SOURCE Inductive Bio, Inc.